Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HCN4 | Q9Y3Q4 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | DRD3 | P35462 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.47 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | DRD5 | P21918 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15047160 | 0.92 | HCN4 (0.58) | GAASMN1; SMN2HCN4MAPTSLC6A4 | |
| SCHEMBL14696925 | 0.86 | GAA (0.68) | GAASMN1; SMN2HCN4MAPTSLC6A4 | |
| SCHEMBL14685767 | 0.85 | GAA (0.66) | GAASMN1; SMN2HCN4MAPTSLC6A4 | |
| SCHEMBL9665585 | 0.84 | MEN1 (0.61) | GAASMN1; SMN2MAPTDRD3HTR1A | |
| SCHEMBL22738846 | 0.83 | GAA (0.64) | GAASMN1; SMN2HCN4MAPTSLC6A4 | |
| SCHEMBL20261656 | 0.83 | GAA (0.64) | GAASMN1; SMN2HCN4MAPTSLC6A4 | |
| SCHEMBL15980993 | 0.82 | GAA (0.62) | GAASMN1; SMN2HCN4MAPTSLC6A4 | |
| SCHEMBL8277872 | 0.82 | ACHE (0.43) | GAASMN1; SMN2HCN4MAPTSLC6A4 | |
| SCHEMBL10667822 | 0.81 | GAA (0.53) | GAASMN1; SMN2HCN4MAPTSLC6A4 | |
| SCHEMBL9032662 | 0.81 | GAA (0.61) | GAASMN1; SMN2HCN4MAPTSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2135861-B2 | Process for the synthesis of the 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one, and its application to the synthesis of ivabradine as well as its addition salts with a pharmaceutically acceptable acid | SERVIER LAB (FR) | 2020-12-16 | — | — | EP | disclosed |
| EP-2607353-B1 | New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid. | SERVIER LAB (FR) | 2014-08-27 | — | — | EP | disclosed |
| US-8513410-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2013-08-20 | — | — | US | disclosed |
| US-8507668-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2013-08-13 | — | — | US | disclosed |
| US-8507668-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2013-08-13 | — | — | US | disclosed |
| WO-2013093220-A1 | METHOD FOR SYNTHESISING IVABRADINE AND THE PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF | LES LABORATOIRES SERVIER (FR) | 2013-06-27 | — | — | WO | disclosed |
| EP-2607354-A1 | Process for the synthesis of ivabradine and addition salts thereof and its pharmaceutically acceptable acid | Les Laboratoires Servier (FR) | 2013-06-26 | — | — | EP | disclosed |
| EP-2607353-A1 | New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid. | Les Laboratoires Servier (FR) | 2013-06-26 | — | — | EP | disclosed |
| US-20130158257-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2013-06-20 | — | — | US | disclosed |
| US-20130158257-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2013-06-20 | — | — | US | disclosed |
| US-20110294999-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2011-12-01 | — | — | US | disclosed |
| WO-2010089475-A1 | NOVEL METHOD FOR THE SYNTHESIS OF IVABRADINE AND THE PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF | LES LABORATOIRES SERVIER (FR) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010072930-A1 | NOVEL METHOD FOR THE SYNTHESIS OF IVABRADINE | LES LABORATOIRES SERVIER (FR) | 2010-07-01 | — | — | WO | disclosed |
| EP-2202225-A1 | New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid. | Les Laboratoires Servier (FR) | 2010-06-30 | — | — | EP | disclosed |
| US-20100160628-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-06-24 | — | — | US | disclosed |
| US-4737495-A | ANTIALLERGENS, ANTISCHEMIC, HYPOTENSIVE AGENTS | DR. KARL TOMAE, GMBH (DE) | 1988-04-12 | — | — | US | disclosed |
| EP-0204349-A2 | Heteroaromatic amine derivatives, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1986-12-10 | — | — | EP | disclosed |
| EP-0065229-B1 | BENZAZEPINES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS PHARMACEUTICAL PREPARATIONS | Dr. Karl Thomae GmbH (DE) | 1985-08-07 | — | — | EP | disclosed |
| US-4490369-A | HYPOTENSIVE, BRRADYCARDIAL | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-12-25 | — | — | US | disclosed |
| EP-0065229-A1 | Benzazepines, process for their preparation and their application as pharmaceutical preparations | Dr. Karl Thomae GmbH (DE) | 1982-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294999-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2F1, CYP2D6 | GAA 885/4885SMN1; SMN2 2145/4885HCN4 37/4885 |
| US-20100160628-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | GAA 885/4885SMN1; SMN2 2145/4885HCN4 37/4885 |
| US-20130158257-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2F1, CYP2D6 | GAA 995/4885SMN1; SMN2 2482/4885HCN4 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.